Get your free ETF data sample from our comprehensive offerings. Start your free trial→
Help us improve your experience. Please confirm your investor type:
Global ETF Survey 2026
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
PJP ETF · Invesco Dynamic Pharmaceuticals ETF
The PJP Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: Dynamic Pharmaceutical Intellidex Index. The PJP ETF provides physical exposure, so by buying it you actually own parts of all the 29 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 7/2/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.+12.20%
Last price
$120.91
1M perf.
+14.49%
1M flows
-€9.9M
AuM
€319M
TER
0.57%
Rating
PJP
$120.91
Performance & flows
Segment for quartile rank
April 2, 2026 → July 2, 2026
Create a free account to view the flows graph
PJP
$121.04
+17.67%
US Health Care
+13.64%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +14.49%  | +17.67% | +50.31% | +65.80%  | +56.48% | +2.30% | +2.30% | +16.44% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
7/2/2026
$121.04
1D NAV change
+2.95%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
29
Inception date
6/23/2005
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Fund
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The Invesco Dynamic Pharmaceuticals ETF (Fund) is based on the Dynamic Pharmaceutical Intellidexâ„ Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including: price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US pharmaceuticals companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialSimilar ETFs in your region
IHE
1M perf.
+9.19%
TER
0.38%
FTXH
1M perf.
+10.79%
TER
0.6%
FHLC
1M perf.
+9.16%
TER
0.084%
VHT
1M perf.
+13.49%
TER
0.09%
IYH
1M perf.
+8.43%
TER
0.38%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +17.67% | +50.31% | +65.80% | +56.48% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
94.10%
Ireland
5.91%
Sectors
Healthcare
100.00%
Diversification
Total weight of top 15 holdings out of 29
Top 15 holdings
Data as of May 31, 2026
Create a free account to view top holdings
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
1-year trailing difference
As of June 30, 2026
Create a free account to view the replication graph
PJP
N/A
Replication quality
Calculated over 12m, as of June 30, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model
Issuer
Invesco
Invesco ID Card
Number of funds
650
Total AuM
€1.06T
Expense ratio range
0.04% - 5.39%
Average expense ratio
0.3497%
Top 5 funds by Invesco
| AuM | ||
|---|---|---|
QQQ | Invesco QQQ ETF | €421.53B |
QQQM | Invesco NASDAQ 100 ETF | €86.08B |
RSP | Invesco S&P 500® Equal Weight ETF | €84.6B |
GGGA | Invesco Global Government Bond UCITS ETF | €38.04B |
SPXS | Invesco S&P 500 UCITS ETF | €35.53B |
Frequently asked questions about PJP
What does Invesco Dynamic Pharmaceuticals ETF, PJP, invest in?
PJP is a Passive ETF. This ETF provides exposure to Equally Weighted US Pharmaceuticals Equities.
Which benchmark or index does PJP replicate?
PJP tracks the Dynamic Pharmaceutical Intellidex Total Return Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of PJP?
PJP carries a total expense ratio (TER) of 0.57%, indicating the annual cost for holding the fund.
When was PJP launched?
PJP was introduced to the market on June 23, 2005. It trades on United States
Who is the ETF issuer of PJP?
Invesco Dynamic Pharmaceuticals ETF, PJP, is provided by Invesco. Learn more about Invesco here.
What is the current assets under management (AUM) of PJP?
PJP oversees €319M in assets as of July 2, 2026.
How has PJP performed lately?
Based on data from July 2, 2026, PJP returned 14.49% over the past month, 17.67% over the last three months and 16.44% year-to-date.
What are the latest inflows or outflows for PJP?
As of July 2, 2026, PJP recorded net flows of -€9.9M over the last month and -€229K year-to-date.
Does PJP distribute dividends?
PJP follows a distributing dividend policy, meaning it pays out income to investors. As of July 2, 2026, its 12-month trailing yield was 0.88%.
What are the main country or region exposures of PJP?
As of May 31, 2026, PJP has significant geographic allocations in USA and Ireland.
In which sector or theme does PJP invest in?
As of May 31, 2026, PJP focuses largely on Healthcare.
How many securities does PJP hold and how diversified is it?
As of May 31, 2026, PJP holds 29 positions in its portfolio, with 65.94% of assets concentrated in its top 15 holdings.
What are the main positions in PJP?
As of May 31, 2026, PJP top three holdings include Eli Lilly & Co., Corcept Therapeutics, Inc. and Liquidia Corp..
What is the base currency of PJP?
The base currency of PJP is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
